[go: up one dir, main page]

MX2019005572A - Complejo medicinal para tratar diabetes tipo 2 y dislipidemia diabetica. - Google Patents

Complejo medicinal para tratar diabetes tipo 2 y dislipidemia diabetica.

Info

Publication number
MX2019005572A
MX2019005572A MX2019005572A MX2019005572A MX2019005572A MX 2019005572 A MX2019005572 A MX 2019005572A MX 2019005572 A MX2019005572 A MX 2019005572A MX 2019005572 A MX2019005572 A MX 2019005572A MX 2019005572 A MX2019005572 A MX 2019005572A
Authority
MX
Mexico
Prior art keywords
diabetes
treating type
medicinal complex
diabetic dyslipidemia
medicinal
Prior art date
Application number
MX2019005572A
Other languages
English (en)
Inventor
Sook Park Ki
Jin Yoon Hye
Hyuk Jung Jong
Won Kim Sung
Yoon Kim Ji
Cheol Yoo Seok
Sun Kim Ri
Soon Ahn Jae
Original Assignee
Lg Chemical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62146049&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2019005572(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lg Chemical Ltd filed Critical Lg Chemical Ltd
Publication of MX2019005572A publication Critical patent/MX2019005572A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se relaciona a un complejo medicinal para tratar efectivamente diabetes tipo 2 y dislipidemia de pacientes diabéticos, más específicamente, la presente invención proporciona un complejo medicinal que comprende un inhibidor de peptidasa IV, gemigliptin o una sal farmacéuticamente aceptable del mismo, y un inhibidor de HMG-CoA reductasa, rosuvastatina o una sal farmacéuticamente aceptable del mismo, para controlar efectivamente los niveles de azúcar en la sangre y mejorar factores de riesgo de la enfermedad cardiovascular.
MX2019005572A 2016-11-15 2017-11-15 Complejo medicinal para tratar diabetes tipo 2 y dislipidemia diabetica. MX2019005572A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20160152195 2016-11-15
PCT/KR2017/012941 WO2018093144A1 (ko) 2016-11-15 2017-11-15 제2형 당뇨병 및 당뇨성 이상지질혈증 치료용 복합제제

Publications (1)

Publication Number Publication Date
MX2019005572A true MX2019005572A (es) 2019-08-14

Family

ID=62146049

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019005572A MX2019005572A (es) 2016-11-15 2017-11-15 Complejo medicinal para tratar diabetes tipo 2 y dislipidemia diabetica.

Country Status (10)

Country Link
KR (1) KR102055894B1 (es)
CN (1) CN109996545A (es)
BR (1) BR112019009709A2 (es)
CO (1) CO2019005207A2 (es)
MX (1) MX2019005572A (es)
PE (1) PE20191502A1 (es)
PH (1) PH12019501028A1 (es)
RU (1) RU2721406C1 (es)
UA (1) UA122847C2 (es)
WO (1) WO2018093144A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119874701A (zh) * 2025-01-14 2025-04-25 深圳格莱恩生物医药科技有限公司 一种吉格列汀马来酸盐晶体及其制备方法与应用
CN120004890B (zh) * 2025-02-17 2025-10-21 安徽峆一药业股份有限公司 一种吉格列汀盐酸盐微晶及其制备方法与应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0322552D0 (en) * 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
AP2007004234A0 (en) * 2005-04-22 2007-12-31 Alantos Pharm Holding Dipeptidyl peptidase-IV inhibitors
EP2464344A2 (en) * 2009-08-13 2012-06-20 Synthon B.V. Pharmaceutical tablet comprising rosuvastatin calcium
CN107115530A (zh) * 2009-11-27 2017-09-01 勃林格殷格翰国际有限公司 基因型糖尿病患者利用dpp‑iv抑制剂例如利拉利汀的治疗
WO2011139256A2 (en) * 2010-05-04 2011-11-10 Bilgic Mahmut Stable rosuvastatin formulations
KR20140013436A (ko) * 2012-07-24 2014-02-05 한미약품 주식회사 메트포르민 및 로수바스타틴을 포함하는 경구용 복합 제제
TWI606848B (zh) * 2012-10-08 2017-12-01 Ｌｇ生命科學股份有限公司 包含格米列汀與美氟明的組合藥物及其製備方法
WO2014080383A1 (en) * 2012-11-26 2014-05-30 Ranbaxy Laboratories Limited Pharmaceutical composition of dipeptidyl peptidase-iv (dpp-iv) inhibitors in combination with other antidiabetics
TW201636015A (zh) * 2013-07-05 2016-10-16 卡地拉保健有限公司 協同性組成物
CN103494788B (zh) * 2013-10-10 2015-08-05 齐晓彤 瑞舒伐他汀钙片的药物组合物及其制备方法
CN104473929B (zh) * 2014-12-17 2018-05-29 深圳翰宇药业股份有限公司 一种西格列汀辛伐他汀缓释组合物

Also Published As

Publication number Publication date
CN109996545A (zh) 2019-07-09
PE20191502A1 (es) 2019-10-22
CO2019005207A2 (es) 2019-08-20
UA122847C2 (uk) 2021-01-06
KR102055894B1 (ko) 2019-12-13
RU2721406C1 (ru) 2020-05-19
BR112019009709A2 (pt) 2019-08-13
WO2018093144A1 (ko) 2018-05-24
KR20180054500A (ko) 2018-05-24
PH12019501028A1 (en) 2020-01-20

Similar Documents

Publication Publication Date Title
MY198928A (en) B7-h3 antibody, antigen-binding fragment thereof and medical use thereof
MX393855B (es) Terapia de combinación que comprende un inhibidor de raf y trametinib
WO2015123423A3 (en) Methods for treating patients with hypercholesterolemia that is not adequately controlled by moderate-dose statin therapy
WO2015054619A3 (en) Use of a pcsk9 inhibitor to treat hyperlipidemia
MY195561A (en) Indole Carboxamide Compounds useful as Kinase Inhibitors
EP3513789A3 (en) Prophylactic and therapeutic agents for fgfr3 diseases
MY199581A (en) Plasminogen replacement therapy for plasminogen-deficiency
MX347372B (es) Uso de metformina en combinacion con un activador de glucoquinasa y composiciones que comprenden metformina y un activador de glucoquinasa.
PH12014500967A1 (en) A medicament for treating anterior eye disease comprising rebamipide and a tear-retaining agent
PH12015500434B1 (en) Combination of sglt2 inhibitors and anti-hypertensive drugs
JOP20210201A1 (ar) مركب لخفض جلوكوز الدم
MX2021007477A (es) Terapia de combinacion con un inhibidor de raf y un inhibidor de cdk4/6 para utilizar en el tratamiento del cancer.
PH12019501028A1 (en) Medicinal complex for treating type 2 diabetes and diabetic dyslipidemia
MX379191B (es) Nuevo uso de clorhidrato de landiolol en el tratamiento a largo plazo de taquiarritmias e hipertension.
WO2015022530A3 (en) Materials and methods relating to pancreatic cancer
MX2019014988A (es) Uso de canagliflozina para reducir o prevenir episodios cardiovasculares en pacientes con diabetes mellitus tipo ii.
EP4324522A3 (en) Methods of treating fabry patients having renal impairment
SG10201903656RA (en) Pharmaceutical composition comprising a beta blocker and an angiotensin converting enzyme inhibitor
FI3448430T3 (fi) Asetyylikoleeniesteraasi-inhibiittorin ja idalopirdiinin käyttö Parkinsonin taudin potilaiden kaatumisten vähentämiseksi
CA3199014A1 (en) Combination therapy for the treatment of a liver disease
FI20145806A7 (fi) Valmisteet alkoholipunoituksen ja alkoholin indusoimien yliherkkyysreaktioiden hoitamiseksi ja ehkäisemiseksi
CR20200096A (es) Composición farmacéutica para la prevención o el tratamiento de enfermedades cardiovasculares acompañádas por diabetes, que include amlodipino, losartán y rosuvastatina, y preparación compuesta que incluye los mismos
MX2019014773A (es) Inhibidores de ccl2.
WO2019013518A3 (ko) 단풍나무 잎 추출물을 포함하는 안압 저하용 조성물
EA201991119A1 (ru) Фармацевтическая композиция, способы лечения и ее применения